Latest Ratios: P/E Ratio 13.3x · EV/EBITDA 6.4x · ROE 588.2%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $2.6B | $3.0B | $2.9B | $2.3B | $9.9B | $7.4B | $10.5B | $6.5B | $7.3B | $5.0B |
| Enterprise Value | $22.0B | $22.5B | $23.6B | $24.4B | $22.5B | $32.0B | $30.7B | $33.2B | $30.0B | $32.0B | $34.3B |
| P/E Ratio → | 13.28 | 16.16 | — | — | — | — | — | — | — | 2.42 | — |
| P/S Ratio | 0.20 | 0.25 | 0.31 | 0.33 | 0.28 | 1.17 | 0.92 | 1.22 | 0.77 | 0.84 | 0.52 |
| P/B Ratio | 5.69 | 6.93 | — | — | 8.74 | — | 12.20 | 9.27 | 2.30 | 1.23 | 1.55 |
| P/FCF | 2.13 | 2.60 | 2.35 | 3.85 | — | 8.67 | 9.21 | 8.61 | 5.10 | 3.74 | 2.81 |
| P/OCF | 1.52 | 1.86 | 1.86 | 2.84 | — | 6.95 | 6.65 | 7.02 | 4.31 | 3.19 | 2.42 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.15 | 2.45 | 2.78 | 2.77 | 3.79 | 3.83 | 3.86 | 3.59 | 3.67 | 3.55 |
| EV / EBITDA | 6.38 | 6.51 | 8.39 | 10.94 | 12.16 | 15.97 | 12.28 | 17.73 | 69.07 | 10.82 | 14.93 |
| EV / EBIT | 9.90 | 11.16 | 12.65 | 15.03 | 15.15 | 18.72 | 23.38 | 24.73 | 60.09 | 57.72 | 28.50 |
| EV / FCF | — | 22.42 | 18.74 | 32.06 | — | 27.98 | 38.28 | 27.14 | 23.73 | 16.39 | 19.12 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.9% | 60.9% | 71.1% | 70.8% | 70.9% | 71.6% | 72.0% | 72.7% | 71.9% | 70.8% | 73.4% |
| Operating Margin | 21.3% | 21.3% | 16.1% | 11.0% | 5.6% | 5.3% | 8.4% | -2.4% | -28.4% | 1.2% | -5.9% |
| Net Profit Margin | 1.5% | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% | -20.7% | -49.5% | 27.6% | -24.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 588.2% | 588.2% | — | -665.2% | -199.1% | -332.0% | -64.2% | -90.3% | -94.7% | 52.2% | -51.9% |
| ROA | 0.6% | 0.6% | -0.2% | -2.2% | -0.8% | -3.1% | -1.7% | -5.8% | -12.8% | 5.9% | -5.2% |
| ROIC | 8.2% | 8.2% | 5.6% | 3.5% | 1.6% | 1.5% | 2.1% | -0.6% | -6.3% | 0.2% | -1.2% |
| ROCE | 10.6% | 10.6% | 7.2% | 4.3% | 2.0% | 1.8% | 2.5% | -0.8% | -8.4% | 0.3% | -1.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 56.36 | 56.36 | — | — | 79.87 | — | 39.55 | 22.79 | 8.63 | 4.28 | 9.16 |
| Debt / EBITDA | 6.14 | 6.14 | 7.76 | 10.05 | 11.24 | 11.32 | 9.57 | 13.83 | 55.87 | 8.60 | 12.98 |
| Net Debt / Equity | — | 52.84 | — | — | 77.70 | — | 38.55 | 19.94 | 8.38 | 4.16 | 8.99 |
| Net Debt / EBITDA | 5.76 | 5.76 | 7.34 | 9.63 | 10.93 | 11.02 | 9.32 | 12.10 | 54.22 | 8.35 | 12.74 |
| Debt / FCF | — | 19.83 | 16.38 | 28.21 | — | 19.31 | 29.08 | 18.52 | 18.63 | 12.65 | 16.32 |
| Interest Coverage | 1.23 | 1.23 | 1.35 | 1.22 | 1.01 | 1.20 | 0.86 | 0.83 | 0.30 | 0.30 | 0.66 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 0.86 | 1.30 | 1.08 | 1.08 | 1.09 | 1.12 | 0.19 | 1.11 | 1.41 |
| Quick Ratio | 1.08 | 1.08 | 0.62 | 0.94 | 0.80 | 0.89 | 0.86 | 0.94 | -0.06 | 0.87 | 1.11 |
| Cash Ratio | 0.32 | 0.32 | 0.17 | 0.22 | 0.14 | 0.11 | 0.12 | 0.52 | 0.19 | 0.17 | 0.15 |
| Asset Turnover | — | 0.40 | 0.36 | 0.32 | 0.32 | 0.29 | 0.26 | 0.25 | 0.31 | 0.23 | 0.22 |
| Inventory Turnover | 2.51 | 2.51 | 1.74 | 1.66 | 2.17 | 2.41 | 2.06 | 2.12 | 2.52 | 2.43 | 2.43 |
| Days Sales Outstanding | — | 82.00 | 81.15 | 83.28 | 80.42 | 76.82 | 71.71 | 78.04 | 81.23 | 89.12 | 94.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.5% | 6.2% | — | — | — | — | — | — | — | 41.3% | — |
| FCF Yield | 47.0% | 38.5% | 42.5% | 26.0% | — | 11.5% | 10.9% | 11.6% | 19.6% | 26.7% | 35.6% |
| Buyback Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.2% | 0.1% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.2% | 0.1% | 0.2% |
| Shares Outstanding | — | $375M | $368M | $365M | $362M | $359M | $355M | $352M | $350M | $352M | $347M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BHC stock.
Bausch Health Companies Inc.'s current P/E ratio is 13.3x. The historical average is 25.5x. This places it at the 31th percentile of its historical range.
Bausch Health Companies Inc.'s current EV/EBITDA is 6.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.6x.
Bausch Health Companies Inc.'s return on equity (ROE) is 588.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.6%.
Based on historical data, Bausch Health Companies Inc. is trading at a P/E of 13.3x. This is at the 31th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bausch Health Companies Inc. has 60.9% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Bausch Health Companies Inc.'s Debt/EBITDA ratio is 6.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Debt burden and revenue volatility
Metrics are mathematically derived from official filings.
Margin Spike Masks Underlying Volatility
BHC's gross margin surged to 99.0% in 2026Q2 from 61.2% in 2026Q1, per reported figures, yet operating margin averaged 22.5% over the prior four quarters, indicating the spike is likely non-recurring.
The 2026Q2 gross margin of 99.0% is an outlier relative to the 57-72% range seen in the preceding nine quarters, suggesting a one-time revenue mix shift or accounting adjustment rather than a sustainable improvement. Operating margin of 40.2% in the same quarter contrasts sharply with the 12-27% range in earlier periods, implying that core profitability remains far lower. Investors should monitor whether the elevated margins persist, as the prior income statement analysis flagged similar anomalies.
ROIC Recovery but Still Subpar
ROIC improved to 6.3% in 2026Q2 from 1.0% in 2026Q1, per financial statements, yet it remains below the cost of capital and well under the 8.2% peer average for Prestige Consumer Healthcare.
The sequential ROIC jump is driven by the anomalous margin spike, not by a fundamental improvement in capital efficiency, as asset turnover has stayed flat at 0.07-0.11 over the period. ROE swung wildly from -31.1% in 2025Q4 to 102.4% in 2025Q2, reflecting negative equity rather than genuine value creation. Based on reported figures, BHC's returns on capital are insufficient to cover its debt burden, suggesting ongoing value destruction unless margins stabilize.
Working Capital Cycle Lengthens
BHC's cash conversion cycle extended to 177 days in 2026Q1 from 165 days in 2025Q4, per reported data, driven by DSO of 82 days and DIO of 150 days, indicating slower cash recovery from sales.
The CCC has hovered between 164 and 215 days over the past ten quarters, with DIO notably high at 150-226 days, reflecting inventory-heavy operations that tie up cash. DPO has remained relatively stable around 53-97 days, suggesting limited supplier leverage. The 2026Q2 data for working capital metrics is unavailable, but the prior trend indicates that efficiency gains are elusive, and the liquidity squeeze in that quarter may be partly attributable to this prolonged cycle.
Debt Metrics Distorted by Equity Erosion
D/EBITDA fell to 0.85 in 2026Q2 from 25.84 in 2026Q1, per reported figures, but this reflects a sharp drop in total debt to $866M, likely due to reclassification, while interest coverage remains thin at 1.87.
The reported debt reduction appears inconsistent with the prior balance sheet analysis, which noted total debt near $21B through 2025, suggesting the 2026Q2 figure may not represent a true deleveraging. Interest coverage of 1.87 in 2026Q2 is barely above the 1.0-1.5 range seen in earlier quarters, indicating that operating income is only marginally sufficient to service interest. Given the negative equity of -$1.8B, leverage ratios based on equity are meaningless, and investors should focus on cash flow coverage of debt.
Liquidity Buffer Collapses
BHC's current ratio plunged to 0.20 in 2026Q2 from 1.32 in 2026Q1, per financial statements, with cash at $900M, suggesting a severe near-term liquidity strain.
The current ratio of 0.20 implies that current liabilities exceed current assets by a wide margin, a dramatic deterioration from the 1.19-1.47 range seen in the prior year. Quick ratio of 0.20 confirms that inventory provides no buffer, as it is already minimal. This liquidity squeeze may force the company to rely on external financing or asset sales, though the reported debt reduction in the same quarter could be related to such actions. The sustainability of operations under this stress warrants close monitoring.
Misapplied EV/EBITDA Multiple
BHC's EV/EBITDA of 6.46 appears cheap, but the metric is distorted by volatile EBITDA and a debt structure that may be understated, per reported figures, making it unreliable for valuation.
The EV/EBITDA multiple is commonly used for leveraged healthcare companies, but BHC's EBITDA has swung sharply due to one-time items and margin anomalies, as seen in the 2026Q2 gross margin spike. Additionally, the reported drop in total debt to $866M in 2026Q2, if not a true extinguishment, would understate EV and artificially lower the multiple. A more appropriate metric would be EV/EBITDAR or a normalized EBITDA that excludes non-recurring gains, or a cash-flow-based multiple like EV/OCF, which better captures the company's actual cash generation.